Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATH 434 (Primary)
Indications Multiple system atrophy
Focus Registrational; Therapeutic Use
Acronyms bioMUSE
Sponsors Alterity Therapeutics

Most Recent Events

19 May 2025 According to an Alterity Therapeutics media release, company announced data from this trial were featured at the 2025 International MSA Congress.
12 May 2025 Results presented in the Alterity Therapeutics media release.
07 May 2025 According to an Alterity Therapeutics media release, company announced oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) will be featured at the 2025 International MSA Congress taking place Friday, May 9, 2025 at 9:10 AM EDT in Boston, MA, USA.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com